Dose Response of Inhaled Tacrolimus in Patients With Moderate Persistent Asthma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Pleven, Bulgaria, 5800
-
Rousse, Bulgaria, 7000
-
Sofia, Bulgaria, 1431
-
Varna, Bulgaria, 9010
-
-
-
-
-
Brno, Czech Republic, 656 91
-
Krhanice, Czech Republic, 257 42
-
Olomouc, Czech Republic, 775 20
-
Sumperk, Czech Republic, 787 52
-
-
-
-
-
Berlin, Germany, 10969
-
Berlin, Germany, 12203
-
Berlin, Germany, 13597
-
Berlin, Germany, 10717
-
Berlin, Germany, 14050
-
Berlin, Germany, 10365
-
Berlin, Germany, 13357
-
Berlin, Germany, 12687
-
Bonn, Germany, 53119
-
Deggendorf, Germany, 94469
-
Dusseldorf, Germany, 40217
-
Hannover, Germany, 30159
-
Munchen, Germany, 80802
-
Potsdam, Germany, 14469
-
Rudersdorf, Germany, 15562
-
Solingen, Germany, 42651
-
Wiesbaden, Germany, 65187
-
-
-
-
-
Budapest, Hungary, 1125
-
Csorna, Hungary, 9300
-
Fuzesabony, Hungary, 3390
-
Nyiregyhaza, Hungary, 4400
-
Szombathely, Hungary, 9700
-
-
-
-
-
Bialystok, Poland, 15-025
-
Krakow, Poland, 31-133
-
Lodz, Poland, 90-153
-
Lodz, Poland, 91-520
-
Lublin, Poland, 20-718
-
Tarnow, Poland, 33-100
-
Wroclaw, Poland, 50-434
-
-
-
-
-
Ekaterinburg, Russian Federation, 620142
-
Moscow, Russian Federation, 143420
-
Moscow, Russian Federation, 107066
-
Rostov-na-Donu, Russian Federation, 344015
-
Smolensk, Russian Federation, 214018
-
St. Petersburg, Russian Federation, 197022
-
St. Petersburg, Russian Federation, 194354
-
St. Petersburg, Russian Federation, 194291
-
St. Petersburg, Russian Federation, 197291
-
-
-
-
-
Dnepropetrovsk, Ukraine, 49044
-
Donetsk, Ukraine, 83003
-
Kiev, Ukraine, 03680
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of asthma
- Patients treated with inhaled corticosteroid
- FEV1 (forced expiratory volume in 1 second)>60% to 80%
Exclusion Criteria:
- Respiratory infection within 2 weeks
- Asthma exacerbation within 90 days
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: R.G.M.vom Amsterdam, MD, Astellas Pharma Europe B.V.
Study record dates
Study Major Dates
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Hypersensitivity, Immediate
- Bronchial Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity
- Asthma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Immunosuppressive Agents
- Immunologic Factors
- Calcineurin Inhibitors
- Tacrolimus
Other Study ID Numbers
Other Study ID Numbers
- FG-506-17-07
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.